Symbiotec Pharmalab Limited
Bookbuilding IPO · NSE, BSE
- Price band
- ₹938 – ₹988
- Lot size
- 15 shares
- Issue amount
- ₹1,757 cr
- Total subscription
- 75.06×
- Opens
- 24 Aug 2026
- Closes
- 27 Aug 2026
- Allotment
- 28 Aug 2026
- Listing
- 1 Sept 2026
Offer at a glance
Issue overview
- Issue size
- 1,77,86,442 shares
- Face value
- ₹2 Per Share
- Minimum investment
- ₹14,070
- Fresh issue
- ₹150.3 cr
- Offer for sale
- ₹1,607 cr
- Registrar
- Link Intime India Private Limited
- Listing exchange
- NSE, BSE
- Maximum investment
- ₹14,820
- Issue type
- Bookbuilding IPO
- Shares before issue
- 6,16,81,496
- Shares after issue
- 6,32,02,757
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 1 | 15 | ₹14,820 |
| sHNI | 14 | 210 | ₹2,07,480 |
| bHNI | 68 | 1,020 | ₹10,07,760 |
Share reservation
Subscription & GMP
Subscription by category
Reported 27 Aug 2026
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| RETAIL | 4,14,237 | 48,46,619 |
| EMPLOYEES | 0 | 23,445 |
| HNIs(10L +) | 8,454 | 1,50,254 |
| HNIs (2-10L) | 4,277 | 2,37,513 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 350.8 | 63,563.89 |
| FIIs | 0 | 12,443.59 |
| FIs | 0 | 36,325.71 |
| Mutual Funds | 0 | 3,457.09 |
| Others | 0 | 11,337.5 |
| RETAIL | 613.9 | 8,379.29 |
| HNIs 2+ | 87.7 | 5,087.08 |
| HNIs 10+ | 175.4 | 15,318.59 |
| EMPLOYEES | 3.3 | 53.85 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-26 | Mar-25 | Mar-24 |
|---|---|---|---|
| EPS | 19 | 17.36 | 18 |
| ROE | 0 | 0 | 0 |
| ROCE | 0 | 0 | 0 |
| RONW | 9.48 | 11.79 | 13.9 |
| PRE IPO(PE) | 55.44 | 0 | 0 |
| POST IPO(PE) | 56.81 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Symbiotec Pharmalab Limited | 55.44 | 988.00 | 2 | 184.69 | 9.48 | 19.1 |
| Concord Biotech Limited | 61.07 | 1,513.40 | 1 | 0 | 14.00 | 24.78 |
| Divi's Laboratories Limited | 87.8 | 8,495.00 | 2 | 631 | 16.50 | 96.75 |
| Cohance Lifesciences Limited | 95.02 | 444.70 | 1 | 0 | 7.00 | 4.69 |
| Laurus Labs Limited | 109.36 | 1,799.00 | 2 | 0 | 16.80 | 16.47 |
Company information
Company profile
Incorporated in 2002, Symbiotec Pharmalab Ltd. is a pharmaceutical and biotechnology company that develops and manufactures active pharmaceutical ingredients, nutritional ingredients, and specialty products for both domestic and international markets. The company focuses on research-based manufacturing, strong quality standards, and sustainable processes, serving industries like pharmaceuticals, nutraceuticals, and wellness with high-quality and innovative products. With over 30 years of experience, it has grown from a small lab-scale steroid API manufacturer into a large, fully integrated company with approvals from global authorities like the US FDA, EU-GMP, and Korea’s Ministry of Food and Drug Safety. As of June 30, 2025, the company operates two large-scale manufacturing facilities with a chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres.
Strengths
- Global Leadership in Steroidal APIs: Symbiotec Pharmalab has strong expertise and an established position in manufacturing corticosteroid and steroidal-hormone APIs, supporting its presence in the global pharmaceutical ingredients market.
- Long-Standing Customer Relationships: The company has built strong relationships with domestic and international customers, supporting recurring business opportunities and market stability.
- Vertically Integrated Manufacturing: The company operates a multi-scale, vertically integrated manufacturing platform, enabling better process control, operational efficiency, and reliable production.
Risk factors
- Regulatory & Quality Compliance Risk: The company's facilities undergo inspections and audits by regulators and customers. Any manufacturing or quality failure could lead to regulatory action, reputational damage, and financial losses.
- Dependence on Export Markets: A significant portion of revenue comes from international customers. Changes in global markets, trade conditions, or difficulties in managing overseas operations could affect revenue and profitability.
- Dependence on Imported Raw Materials: The company sources some raw materials from countries such as China and the United States. Import restrictions, geopolitical developments, or supply disruptions could affect raw material availability and increase costs.
Promoters
Anil Satwani
Kashish Satwani
Sushil Satwani
Satwani Holdings LLP
Registrar & documents
Lead manager
Jm Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited, Nomura Financial Advisory And Securities (India) Private Limited
Registrar & contacts
Link Intime India Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh, 453331
+91 731 667 6405
[email protected]Company website ↗Understanding SYMBIOTEC IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.